Probucol

Clinical data
ATC code|

* C10AX02 (WHO)

Identifiers

IUPAC name

* 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl- 4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol

PubChem CID|

* 4912

E number| {{#property:P628}}
ECHA InfoCard| {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula| C31H48O2S2
Molar mass| 516.844 g/mol

WikiDoc Resources for Probucol

Articles

Most recent articles on Probucol

Most cited articles on Probucol

Review articles on Probucol

Articles on Probucol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Probucol

Images of Probucol

Photos of Probucol

Podcasts & MP3s on Probucol

Videos on Probucol

Evidence Based Medicine

Cochrane Collaboration on Probucol

Bandolier on Probucol

TRIP on Probucol

Clinical Trials

Ongoing Trials on Probucol at Clinical Trials.gov

Trial results on Probucol

Clinical Trials on Probucol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Probucol

NICE Guidance on Probucol

NHS PRODIGY Guidance

FDA on Probucol

CDC on Probucol

Books

Books on Probucol

News

Probucol in the news

Be alerted to news on Probucol

News trends on Probucol

Commentary

Blogs on Probucol

Definitions

Definitions of Probucol

Patient Resources / Community

Patient resources on Probucol

Discussion groups on Probucol

Patient Handouts on Probucol

Directions to Hospitals Treating Probucol

Risk calculators and risk factors for Probucol

Healthcare Provider Resources

Symptoms of Probucol

Causes & Risk Factors for Probucol

Diagnostic studies for Probucol

Treatment of Probucol

Continuing Medical Education (CME)

CME Programs on Probucol

International

Probucol en Espanol

Probucol en Francais

Business

Probucol in the Marketplace

Patents on Probucol

Experimental / Informatics

List of terms related to Probucol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

## Overview

[edit | edit source]

Probucol is an anti-hyperlipidemic drug[1] initially developed in the treatment of coronary artery disease.

However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.

Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.

Probucol is associated with QT interval prolongation.

## Mechanism

[edit | edit source]

Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.[2] Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.

It is believed to act at ABCA1.[3]

It also lowers levels of HDL.[4]

## References

[edit | edit source]

1. ↑ Yamamoto A (December 2008). "A Uniqe Antilipidemic Drug - Probucol". J. Atheroscler. Thromb. 15 (6): 304–5. doi:10.5551/jat.E621. PMID 19075491.
2. ↑ "Probucol. Drugs.com web site. [1]
3. ↑ Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH (December 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol. 24 (12): 2345–50. doi:10.1161/01.ATV.0000148706.15947.8a. PMID 15514211.CS1 maint: Multiple names: authors list (link)
4. ↑ Miida T, Seino U, Miyazaki O; et al. (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis. 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

Template:Lipid modifying agents
*[CID]: Compound ID